Ligand Pharmaceuticals Incorporated
LGND
$210.99
$3.191.54%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 244.06% | 1,735.15% | 109.34% | -149.28% | -270.93% |
| Total Depreciation and Amortization | -4.79% | 1.81% | -8.56% | -5.20% | -3.24% |
| Total Amortization of Deferred Charges | 40.65% | 30.98% | -10.50% | 25.80% | 27.01% |
| Total Other Non-Cash Items | -145.14% | -485.61% | -86.60% | 115.48% | 1,162.12% |
| Change in Net Operating Assets | -19.94% | -249.07% | 18.91% | -162.70% | 172.55% |
| Cash from Operations | 61.27% | -64.17% | 18.66% | -235.84% | 253.02% |
| Capital Expenditure | 98.74% | 97.48% | 47.55% | -103.81% | -70.74% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 73.60% | -669.82% | 80.77% | 239.18% | -284.22% |
| Cash from Investing | 53.13% | -659.98% | 80.52% | 229.64% | -275.56% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -16.67% | -1,132,460.00% | -75.00% | -40.00% | -20.00% |
| Issuance of Common Stock | -58.58% | -53.56% | -13.75% | -72.41% | 243.96% |
| Repurchase of Common Stock | 82.22% | -12,075.20% | -- | -189.04% | -652.92% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -422.88% | 25,041.90% | 12,219.30% | -73.17% | 87.57% |
| Cash from Financing | -59.14% | 643.73% | 57.99% | -138.97% | 283.59% |
| Foreign Exchange rate Adjustments | 61.89% | -206.10% | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 309.20% | 57.67% | 161.59% | -189.61% | 180.62% |